glucagon-like peptide-1 (GLP-1) Archive — Page 2 of 3
-
October 28, 2021
Pancreatic beta-cell booster
Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications. -
May 20, 2021
Type 2 diabetes medication shown to benefit asthma patients
Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation. -
February 18, 2021
Gene variant and glucose metabolism
Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study. -
November 3, 2020
New treatment for a rare obesity
Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity. -
January 10, 2019
Bile acids mediate metabolic benefits of weight-loss surgery
A team of Vanderbilt investigators has pinpointed the role of bile acids and a specific signaling pathway in the positive metabolic effects of weight-loss surgery. -
July 12, 2018
Team explores diabetes drug’s ability to treat RSV infection
A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease. -
September 21, 2017
Pancreatic islets study may spur diabetes treatment advances
Investigators in the Vanderbilt Diabetes Research and Training Center (VDRTC) and collaborators at Stanford University have discovered new insights into the molecular mechanisms of cell proliferation in juvenile human pancreatic islets, information that could lead to new treatments for diabetes.